ADAM8 Double Nickase Plasmid (h): sc-407606-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ADAM8 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- ADAM8 Double Nickase Plasmid (h) and ADAM8 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting ADAM8. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ADAM8 Antibody (F-5): sc-374421
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ADAM8 Double Nickase Plasmid (h) | sc-407606-NIC | 20 µg | $410.00 | |||
ADAM8 Double Nickase Plasmid (h2) | sc-407606-NIC-2 | 20 µg | $410.00 |
ADAM8 (a disintegrin and metalloproteinase 8) is a membrane-anchored protease that regulates pericellular proteolysis, ectodomain shedding, and cell–cell/cell–matrix interactions. Through its metalloprotease and disintegrin domains, ADAM8 can influence leukocyte adhesion and migration, remodeling of extracellular matrix, and inflammatory signaling, integrating into pathways that coordinate tissue injury responses. Altered ADAM8 expression has been linked to dysregulated immune cell trafficking and protease-driven microenvironment changes observed across chronic inflammatory conditions and multiple tumor contexts, supporting its use as a mechanistic node in studies of invasion, metastasis-associated processes, and immune modulation. These features make ADAM8 a relevant target for dissecting proteolytic signaling networks and cell-surface receptor regulation in human cells.
ADAM8 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the ADAM8 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within ADAM8. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt ADAM8 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of ADAM8-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.